- Home
- CX vs SRPT Comparison
CX vs SRPT Comparison
Compare CX & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CX
- SRPT
- Stock Information
- Founded
- CX 1906
- SRPT 1980
- Country
- CX Mexico
- SRPT United States
- Employees
- CX N/A
- SRPT N/A
- Industry
- CX Building Materials
- SRPT Biotechnology: Pharmaceutical Preparations
- Sector
- CX Industrials
- SRPT Health Care
- Exchange
- CX Nasdaq
- SRPT Nasdaq
- Market Cap
- CX 8.5B
- SRPT 9.8B
- IPO Year
- CX 1999
- SRPT 1997
- Fundamental
- Price
- CX $6.26
- SRPT $75.17
- Analyst Decision
- CX Buy
- SRPT Buy
- Analyst Count
- CX 6
- SRPT 21
- Target Price
- CX $7.70
- SRPT $164.05
- AVG Volume (30 Days)
- CX 11.1M
- SRPT 2.2M
- Earning Date
- CX 04-24-2025
- SRPT 04-30-2025
- Dividend Yield
- CX 1.31%
- SRPT N/A
- EPS Growth
- CX 417.83
- SRPT N/A
- EPS
- CX 0.06
- SRPT 2.34
- Revenue
- CX $16,200,000,000.00
- SRPT $1,901,979,000.00
- Revenue This Year
- CX $7.56
- SRPT $67.83
- Revenue Next Year
- CX $5.63
- SRPT $25.66
- P/E Ratio
- CX $9.33
- SRPT $31.48
- Revenue Growth
- CX N/A
- SRPT 52.97
- 52 Week Low
- CX $5.00
- SRPT $72.17
- 52 Week High
- CX $9.27
- SRPT $173.25
- Technical
- Relative Strength Index (RSI)
- CX 50.66
- SRPT 30.79
- Support Level
- CX $5.89
- SRPT $73.05
- Resistance Level
- CX $6.17
- SRPT $103.32
- Average True Range (ATR)
- CX 0.18
- SRPT 4.23
- MACD
- CX -0.00
- SRPT -2.53
- Stochastic Oscillator
- CX 53.23
- SRPT 9.45
About CX Cemex S.A.B. de C.V. Sponsored ADR
Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and services.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.